

SATELLITE SYMPOSIUM
ON FRIDAY
OCTOBER 24TH
6:30PM-7:30PM

FUTURE OF
IMMUNOTHERAPIES IN
THE TREATMENT OF CTCL

Symposium co-chaired by Pr Martine Bagot
and Pr Armand Bensussan (Hôpital Saint-
Louis, Paris) and Pr Youn Kim (Stanford's
Cutaneous Lymphoma Group, CA, USA)



Symposium sponsored by  innate pharma

www.innate-pharma.com

(HAPPY) IMMUNOTHERAPY HOURS

THE SYMPOSIUM WILL FOCUS ON THE IMPORTANCE OF THE IMMUNE SYSTEM IN THE CONTROL OF CANCER, PARTICULARLY IN CTCL, AND ITS MANIPULATION IN CANCER THERAPY:

- **CANCER IMMUNOTHERAPY: NOVEL NK CELL-BASED APPROACHES**

DR NICOLAÏ WAGTMANN, CHIEF SCIENTIFIC OFFICER, INNATE PHARMA.

- **ANTIBODY- AND FUSION PROTEIN-BASED THERAPIES IN CTCL: SUCCESSES, CHALLENGES AND FUTURE DIRECTIONS**

DR LARISA GESKIN, ASSOCIATE PROFESSOR OF DERMATOLOGY AT COLUMBIA UNIVERSITY MEDICAL CENTER AND DIRECTOR OF THE COMPREHENSIVE SKIN CANCER CENTER (CSCC).

- **IMMUNOTHERAPY-BASED STRATEGIES IN CTCL: CLINICAL EXPERIENCE WITH IMMUNE CHECKPOINT INHIBITORS**

DR HOLBROOK KOHRT, PHYSICIAN AND ASSISTANT PROFESSOR OF MEDICINE (ONCOLOGY) AT THE STANFORD UNIVERSITY MEDICAL CENTER.

DR NICOLAÏ WAGTMANN has a research background in NK cell biology, and is a pioneer of pharmacological approaches targeting innate immunity in cancer and inflammation. Formerly Vice President of Research and Development at Novo Nordisk A/S, he led a long-standing collaboration with Innate Pharma SA, resulting in a portfolio of first-in-class therapeutic antibodies targeting cells of the innate immune system. In 2013, he joined Innate Pharma SA in Marseilles, France as Chief Science Officer.



DR LARISA GESKIN is a world renowned specialist in the diagnosis and management of cutaneous lymphomas and other cancers of the skin. Her other areas of expertise include melanoma screening, prevention, medical and surgical therapy, and management of high risk for skin cancer populations.



Dr. Geskin is using state-of-the-art methods in melanoma screening and surveillance including Mole Mapping and dermoscopy. She was involved in development of novel melanoma detection methods.

Dr. Geskin's team aims to provide multidisciplinary care to skin cancer patients, to conduct cutting edge clinical and basic science research, and to train medical students, residents and fellows in the area of cutaneous oncology.

DR HOLBROOK KOHRT currently investigates novel therapeutic strategies to enhance anti-tumor immunity. He trained in Internal Medicine at Stanford through the Clinical Investigator Pathway and completed fellowship in Hematology and Oncology at Stanford with a research focus on preclinical models of novel immunomodulatory antibodies.



As faculty at Stanford, Dr. Kohrt is developing novel vaccine strategies which induce tumor antigen specific immunity prior to infusing the donor inoculum and improve graft-versus-tumor reactions without exacerbation of graft-versus-host disease.

His studies also include efforts to identify and develop immunomodulatory antibodies targeting immune effector cells subsets, such as natural killer cells, which enhance the anti-tumor activity of tumor-targeting antibodies.